Herpes virus outbreak after dermal filler injection is a rare but troublesome complication, caused by virus reactivation. Herpes simplex virus 1 (HSV-1) is often involved (according to data released by the FDA, the incidence does not exceed 1.45% of cases), whereas herpes zoster (HSZ) onsets are more rare. 1 Many adverse effects after facial filler injections have been widely described and discussed by several authors, 2, 3 but the literature is scant regarding HSV and HZV reactivations after hyaluronic acid filler injections.
Viral agents and infection
The family of herpesviridae includes HSV-1, herpes simplex virus 2 (HSV-2), herpes zoster virus, Epstein-Barr virus, cytomegalovirus, human herpes virus 6, human herpes virus 7, and human herpes virus 8. Clinical reactivations after dermal filler injections have been described for herpes simplex and herpes zoster viruses. These viral agents have in common the double-stranded linear DNA that replicates inside the nucleus and their capability for latent and persistent infection.
Herpes simplex viruses are characterized by mucocutaneous infections, although systemic infections have been rarely described. HSV-1 is classically associated with labial infections and cranial localizations, whereas HSV-2 consists of the etiologic agent of herpes simplex genitalis. Recently, it has been shown that in some populations, HSV-1 is the most frequent cause of herpes genitalis. 4 The varicella zoster virus occurs both in children (primary infection, chicken pox) and adults (secondary infection, herpes zoster). The virus penetrates through the respiratory tract, causing a viremic phase, characterized by a generalized eruption of vesicles, followed by infiltration of inflammatory cells and pustule formation.
During facial dermal filler injections, virus reactivations can be provoked by direct damage to the axon by the needle. In addition, tissue manipulation and inflammatory reaction after filler injection could play a role in viral reactivation. The traumatic damage is believed to mainly cause infection reactivation, but the hyaluronic acid itself has been demonstrated to act as a protective agent, preventing viral replication. 5 Severe infective complications can occur in immunocompromised patients. An accurate preoperative interview can underline the necessity of an oral prophylaxis, thus avoiding further complications. In immunocompetent patients, 2 viral reactivations per year can be observed, whereas in immunocompromised patients, as many as 6 episodes can be detected.
When defects of the immune response are suspected, the severity of this condition should be investigated. Although in mild cases, a short prophylaxis can be attempted, in severe cases, the treatment should be prolonged.
Although latent infection can show no clinical signs, histologic findings in the epidermal layer can be pathognomonic. 6 The incubation period lasts 5 to 6 days, although the first symptoms can be observed even 3 or 4 days after the procedure. In this period, discomfort, drooling, and cervical/ mandibular lymph node hypertrophy can be experienced. Circular ulcerations, covered by a yellowish film with a surrounding erythematous rib, can occur ( Figure 1 ).
localization
Virus reactivation will appear in the area where the filler has been injected (the most common sites are the perioral area and the nasolabial folds). In some cases, virus reactivation can extend and affect neighboring areas. 7 The viral outbreak is commonly observed 24 to 48 hours after filler injection.
Although the site of reactivation depends on the injection site, the pattern of reactivation is determined by the infective agent, mainly HSV-1 and HZV. Herpes simplex virus infection is subclinical in most cases, 8 establishing latent infections in the sensory ganglia 9 (the trigeminal ganglion is often involved by HSV-1). During latency, few viral genes are expressed and replication is inhibited. In individuals infected by HSV-1, just 0.1% to 3% of ganglial neurons contain the viral genome, usually resulting in 1 to 20 copies per cell. 10 An accurate medical history should therefore be gained, focusing on those symptoms that could underline a previous herpetical outbreak (eg, vesicles, erythema, desquamation), localization, and possibly their relation with past procedures with dermal fillers. Herpes zoster reactivations have mainly been observed along the ophthalmic branch (V1) of the trigeminal nerve; nevertheless, these outbreaks are more infrequent, usually occurring in immunocompromised individuals. 11 According to Chisholm and Lopez, 6 the dermatomes from T3 to L3 are most frequently affected. In some cases, pain is the only clinical sign of disease, without vesicles and ulcers. Herpes zoster outbreaks share the same pattern as HSV, ascending in a retrograde manner through the periaxonal sheath of sensory nerves, thus infecting and replicating in the cutaneous or mucous epithelial cells. Although cell immunity is able to contain the infection severity, the virus is able to evade the immune response.
antiViral therapy
Therapy for symptomatic HSV relies on few antiviral drugs: acyclovir, valacyclovir hydrochloride, and famciclovir. The substances are converted in the active drug by viral thymidine kinase inside the infected cell, thus gaining specificity and raising the safety margin. The current therapeutic approach can be divided into 3 groups: intermittent episodic therapy (IET), chronic suppressive therapy (CST), and intermittent suppressive therapy (IST). 12 Intermittent episodic therapy is administered for acute episodes of a chronic disease, CST is applied for frequent recurrences with severe functional impairment and disfigurement, and IST is employed to prevent oral and genital herpes for short periods.
Two treatment modalities can be used concurrently: ISI and IET. The former acts to prevent viral reactivation, and the latter is applied for herpetical outbreaks. Intermittent episodic therapy is recommended before dermal filler injection in cases of recurrent herpetical episodes by HSV (>3 reactivations/y) with 400 mg acyclovir 3 times per day for 10 days. 12 Alternatively, 1 g valacyclovir twice per day for 7 days can be employed.
Intermittent episodic therapy is administered after filler injection in cases of HSV outbreak, with 400 mg acyclovir 3 times per day for 10 days or 1 g valacyclovir hydrochloride twice per day for 7 days. For shingles, 800 mg acyclovir 5 times a day or 1 g valacyclovir twice per day for 7 days can be employed. In cases of frequent recurrences and severe outbreaks, any procedures with hyaluronic acid fillers should be discouraged, and chronic suppressive therapy may be considered (Table 1 ).
In conclusion, the cosmetic practitioner should always gain an accurate medical interview focusing on past herpetical reactivations and previous procedures with dermal fillers. A proper clinical examination and a strict follow-up after the procedure are essential to prevent and treat effectively any herpetical outbreak.
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